TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9033316

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuit
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass circuit
Number of subjects: 30
Study: 8345794

Group type: EXPERIMENTAL
Intervention: Oral therapy (conjugated equine estrogens, 0.625 mg/d continuous + levonorgestrel, 0.075 mg/d for 12 days of each 28‐day cycle)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Transdermal therapy (estradiol 17 beta, 0.05 mg/d continuous + norethindrone acetate, 0.25 mg/d for 14 days of each 28‐day cycle)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Untreated control group (30 postmenopausal women not seeking HRT)
Number of subjects: 61
Study: 3733414

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (untreated by PP)
Number of subjects: 5
Study: 31961284

Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG) intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Education Control Group (EC)
Number of subjects: 19
Study: 29807958

Group type: EXPERIMENTAL
Intervention: Group III (laser)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group II (magic foam)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group I (retraction cord impregnated with aluminum chloride)
Number of subjects: 45
Study: 27855699

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Treatment for Adolescents (PE-A)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Supportive Counselling (SC)
Number of subjects: 11
Study: 24132138

Group type: EXPERIMENTAL
Intervention: Stretching Training (ST)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 28
Study: 25885496

Group type: EXPERIMENTAL
Intervention: Normal saline 4 mL/kg (group L)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline 10 mL/kg (group H)
Number of subjects: 80
Study: 20685760

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT), biweekly for 12 weeks, starting from 15RM to 8RM
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group maintained usual daily activity level
Number of subjects: 38
Study: 19071987

Group type: EXPERIMENTAL
Intervention: Culturally specific (CS) smoking cessation guide
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard smoking cessation guide
Number of subjects: 182
Study: 15673385

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 55

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 55
Study: 12377641

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin
Number of subjects: 618

Group type: COMPARATOR
Intervention: Paclitaxel/cisplatin
Number of subjects: 618
Study: 10530408

Group type: EXPERIMENTAL
Intervention: Ig heavy chain (IgH) gene rearrangements using primers directed to framework regions (FR) 1, 2 and 3
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: T-cell receptor (TCR) gene rearrangements using primers hybridising to TCR delta and gamma genes
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combination of all five primer sets
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Analysis of oligoclonal patterns
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Comparative analysis of samples from different compartments
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Detection of large size PCR products (540-715 bp)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Minimum of three targets for detection
Number of subjects: 91
Study: 8750162

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not treated with interferon)
Number of subjects: 26
Study: 2074246

Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 3791

Group type: COMPARATOR
Intervention: Cefotaxime or Cefuroxime
Number of subjects: 3791
Study: 6781589

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tubigrip support
Number of subjects: 0

Group type: COMPARATOR
Intervention: X-ray examination
Number of subjects: 0
Study: 6092555

Group type: EXPERIMENTAL
Intervention: CAV plus thoracic irradiation (4,000 rad TD, split course)
Number of subjects: 291

Group type: COMPARATOR
Intervention: CAV without thoracic irradiation
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: CAV plus brain irradiation
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: CAV plus brain irradiation plus thoracic irradiation
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: CAV plus thoracic irradiation
Number of subjects: 291

Group type: COMPARATOR
Intervention: CAV and brain irradiation without thoracic radiotherapy
Number of subjects: 291
Study: 29920211

Group type: EXPERIMENTAL
Intervention: Blended dairy (3 servings/day for 4 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (rs6720173‐GG, rs3808607‐G, and rs760241‐A genotypes)
Number of subjects: 16
Study: 27294502

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota probiotic (PRO)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 243
Study: 24401211

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (2 g/day for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs
Number of subjects: 29
Study: 22206609

Group type: EXPERIMENTAL
Intervention: Low-tube voltage (80 kVp) 320-detector row volume CT angiography (L-VCTA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional-tube voltage (120 kVp) volume CT angiography (C-VCTA)
Number of subjects: 48
Study: 20435965

Group type: EXPERIMENTAL
Intervention: Group-based intervention (12-week programme plus three booster sessions)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 84
Study: 17934183

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15858300

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) as a pulpotomy medicament
Number of subjects: 0
Study: 11811169

Group type: EXPERIMENTAL
Intervention: i.v. CRF as a 1.0-microg/kg bolus followed by a constant infusion (1.0 microg/kg/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 10423023

Group type: EXPERIMENTAL
Intervention: Surgery for peptic ulcer disease
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Thyroid replacement
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Chronic anticoagulation
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Gastrectomy with Billroth II reconstruction
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 438
Study: 7554762

Group type: EXPERIMENTAL
Intervention: Acute hypoxia at 3440 m
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subjects with symptoms of acute mountain sickness at 4120 or 5200 m
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Raised intracranial pressure
Number of subjects: 24
Study: 2405994

Group type: EXPERIMENTAL
Intervention: Transurethral debulking surgery combined with upfront CMV chemotherapy plus cisplatin and 4000 cGy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant MCV chemotherapy for selective bladder preservation
Number of subjects: 0
Study: 6115808

Group type: EXPERIMENTAL
Intervention: LH-RH treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 62
Study: 31147359

Group type: EXPERIMENTAL
Intervention: Morita Therapy (MT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 16
Study: 28685888

Group type: EXPERIMENTAL
Intervention: Phase 2 in-person health survey invitation
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Phase 1 household enumeration questionnaire
Number of subjects: 599
Study: 27314331

Group type: EXPERIMENTAL
Intervention: Darmocare Pre(®) (prebiotic formulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 60
Study: 25825102

Group type: EXPERIMENTAL
Intervention: 8% lignocaine gel
Number of subjects: 42

Group type: COMPARATOR
Intervention: 15% lignocaine spray
Number of subjects: 42
Study: 21932114

Group type: EXPERIMENTAL
Intervention: Monthly minodronate at 30 mg
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Monthly minodronate at 50 mg
Number of subjects: 692

Group type: COMPARATOR
Intervention: Daily minodronate at 1 mg
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: All groups (30 mg, 50 mg, and 1 mg daily)
Number of subjects: 692
Study: 19188545

Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy (gemcitabine plus carboplatin, paclitaxel, or cisplatin)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy
Number of subjects: 85
Study: 18265541

Group type: EXPERIMENTAL
Intervention: Twelve‐week heart health education and physical activity program
Number of subjects: 120
Study: 16318830

Group type: EXPERIMENTAL
Intervention: hioxofilcon A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: omafilcon A
Number of subjects: 40
Study: 11725940

Group type: EXPERIMENTAL
Intervention: Daily records of physical activity (intervention group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No records (control group)
Number of subjects: 49
Study: 9164824

Group type: EXPERIMENTAL
Intervention: 150 mg Ca as AAACa after each meal and 450 mg at bedtime
Number of subjects: 9

Group type: COMPARATOR
Intervention: 300 mg after each meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8232735

Group type: EXPERIMENTAL
Intervention: Conventionally Fractionated Radiotherapy (CFR)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Large Fractionated Radiotherapy (LFR)
Number of subjects: 49
Study: 3111280

Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2 and 65% O2; Duration: Not specified
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo; Duration: Not specified
Number of subjects: 8
Study: 31200662

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Revascularization
Number of subjects: 92
Study: 28408411

Group type: EXPERIMENTAL
Intervention: Active Avoidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoked Extinction
Number of subjects: 0
Study: 25880814

Group type: EXPERIMENTAL
Intervention: OXCAP-RT (oxaliplatin 85 mg/m2 Day 1,15,29; capecitabine 625 mg/m2 twice daily on days of RT; RT-45 Gy/25 fractions/5 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: CarPac-RT (Carboplatin AUC2 and paclitaxel 50 mg/m2 Day 1,8,15,22,29; RT-45 Gy/25 fractions/5 weeks)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both OXCAP-RT and CarPac-RT
Number of subjects: 76
Study: 23674855

Group type: EXPERIMENTAL
Intervention: Nigella sativa (N. sativa) administered for three months at a dose of 450 mg three times daily
Number of subjects: 30
Study: 21270583

Group type: EXPERIMENTAL
Intervention: Intradermal buffered lidocaine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Intradermal bacteriostatic normal saline
Number of subjects: 148
Study: 19207871

Group type: EXPERIMENTAL
Intervention: Short vaccination protocol: 20 microg i.m. once a week for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard vaccination protocol: three doses of 40 microg i.m. at months 0, 1 and 6
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard vaccination protocol
Number of subjects: 51
Study: 16952539

Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness plication
Number of subjects: 159

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 159
Study: 15032280

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin (TP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Carboplatin/cyclophosphamide (CP)
Number of subjects: 18
Study: 11733887

Group type: EXPERIMENTAL
Intervention: Subjects with stroke
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 19
Study: 8602592

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) 1000 mg/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) 1000 mg/d plus 5 micrograms (200 IU) vitamin D/d
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Milk (1 L more than usual daily diet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo tablets (three tablets daily)
Number of subjects: 20
Study: 1548922

Group type: EXPERIMENTAL
Intervention: Cervical anastomosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thoracic anastomosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subtotal esophagectomy
Number of subjects: 60
Study: 2865502

Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min
Number of subjects: 129

Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 129
Study: 30919515

Group type: EXPERIMENTAL
Intervention: Upper-body exercise (arm-cranking)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Upper-body exercise (arm-cranking) at matched ventilations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Upper-body exercise (arm-cranking) at 100% V̇E,UBE
Number of subjects: 8
Study: 30231777

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 27228564

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional approach (non-US guidance)
Number of subjects: 40
Study: 24343325

Group type: EXPERIMENTAL
Intervention: 3 repetition maximum (RM) squat followed by countermovement jump (CMJ)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group performed CMJ at 15 seconds and at 4, 8, 12, 16, and 20 minutes
Number of subjects: 22
Study: 22328280

Group type: EXPERIMENTAL
Intervention: Gambling-like alternative (low probability, high payoff)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-regulatory depletion manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of gambling activity
Number of subjects: 0
Study: 20926016

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (non‐placebo, non‐treatment)
Number of subjects: 42
Study: 19001742

Group type: EXPERIMENTAL
Intervention: FDP 200 mg/kg infused intravenously before anesthesia
Number of subjects: 106

Group type: COMPARATOR
Intervention: 5% glucose infusion (control group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: FDP 200 mg/kg
Number of subjects: 106
Study: 16380703

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-like Growth Factor-I (IGF-I)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Psoriasis Area and Severity Index (PASI)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control Group (Healthy Persons)
Number of subjects: 85
Study: 12417879

Group type: EXPERIMENTAL
Intervention: Albuterol MDI (0 to 576 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol MDI (90 microg and 180 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol MDI
Number of subjects: 15
Study: 10599545

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate/hMG
Number of subjects: 324

Group type: COMPARATOR
Intervention: GnRH agonist/hMG
Number of subjects: 324
Study: 7547766

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (0.625 mg conjugated equine oestrogens with 0.15 mg cyclic norgestrel for 12 days per 28 day cycle)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 1437059

Group type: EXPERIMENTAL
Intervention: Clotrimazole troches, 10 mg, five times daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nystatin suspension, 500,000 units, four times daily
Number of subjects: 34
Study: 3980803

Group type: EXPERIMENTAL
Intervention: Trimethylpsoralen bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (1 mg/kg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bath PUVA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etretinate (1 mg/kg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bath PUVA (maintenance therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etretinate (25‐50 mg daily)
Number of subjects: 25
Study: 30019357

Group type: EXPERIMENTAL
Intervention: Masticatory muscle stretching exercises for 10 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (received sleep hygiene advice only)
Number of subjects: 24
Study: 28228411

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVZ)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dexamethasone implant (DEX)
Number of subjects: 61
Study: 23271686

Group type: EXPERIMENTAL
Intervention: Automatic suturing instrument (Group 2)
Number of subjects: 1464

Group type: COMPARATOR
Intervention: Deschamps ligature carrier (Group 1)
Number of subjects: 1464
Study: 21854488

Group type: EXPERIMENTAL
Intervention: PIV cannulation with the VeinViewer (VV)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard PIV cannulation (SC)
Number of subjects: 323
Study: 19028519

Group type: EXPERIMENTAL
Intervention: Neighborhood environment-focused website
Number of subjects: 106

Group type: COMPARATOR
Intervention: Motivational-information website
Number of subjects: 106
Study: 17910218

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (CP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (CP) with potassium nitrate and fluoride (PF)
Number of subjects: 20
Study: 12764624

Group type: EXPERIMENTAL
Intervention: Metformin therapy (2x850 mg/day for 8 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (only gonadotropin induction)
Number of subjects: 32
Study: 11527172

Group type: EXPERIMENTAL
Intervention: Inchin‐ko‐to (ICKT) 0.15 g/kg per day administered orally for 1 year
Number of subjects: 18
Study: 9283530

Group type: EXPERIMENTAL
Intervention: Early intraaortic balloon counterpulsation (IABP) within one calendar day of enrollment
Number of subjects: 310

Group type: COMPARATOR
Intervention: No intraaortic balloon counterpulsation (IABP) (insertion on or after day 2 or never)
Number of subjects: 310
Study: 7920930

Group type: EXPERIMENTAL
Intervention: Step-down protocol (FSH +/‐ hMG without LHRH agonist)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Step-up protocol (FSH +/‐ hMG without LHRH agonist)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Step-down protocol (FSH +/‐ hMG with LHRH agonist)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Step-up protocol (FSH +/‐ hMG with LHRH agonist)
Number of subjects: 26
Study: 3532967

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) 5 mg/kg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 20
Study: 29407633

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No anticoagulant (control)
Number of subjects: 50
Study: 27160844

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer (CCT) combined with cognitive-behavioural group aftercare (AC) for 12 weeks and 4 weeks respectively.
Number of subjects: 0
Study: 25200640

Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 78
Study: 22747652

Group type: EXPERIMENTAL
Intervention: Perceived drug treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Perceived placebo treatment
Number of subjects: 36
Study: 20585224

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 124
Study: 18842969

Group type: EXPERIMENTAL
Intervention: Patient-oriented intervention by a practice nurse
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group (no patient-oriented intervention)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Patient-oriented intervention
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study: 15869544

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (0.05%) applied once daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (0.05%) applied on alternate days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Initial once-daily followed by alternate-day application
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control site with vehicle application
Number of subjects: 26
Study: 12693197

Group type: EXPERIMENTAL
Intervention: Training phase with sequences of letters generated by a finite-state grammar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group responding to randomized sequences
Number of subjects: 0
Study: 10595053

Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard post-discharge care
Number of subjects: 78
Study: 8712437

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0% end-tidal concentration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isoflurane at 0.85% end-tidal concentration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.55% and 0.7% end-tidal concentrations
Number of subjects: 8
Study: 1934546

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Papaveretum
Number of subjects: 0
Study: 7253867

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE)
Number of subjects: 728
Study: 30994371

Group type: EXPERIMENTAL
Intervention: Breastfeeding cessation reasons
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Returning to work/school
Number of subjects: 221
Study: 28767570

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 5mg (5mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Morphine hydrochloride 5mg (5mL)
Number of subjects: 80